LAUSR

Traditional chemotherapy has faced tough challenges of systemic toxicity, hypoxia resistance, and inadequacy of monotherapy. Developing the tumor‐specific O2‐supply‐enhanced chemotherapy without toxic drugs while combing other precise treatments can substantially improve therapeutic efficacy. Herein, a CeO2‐enriched CuO nanozyme with O2 supply and oxidative stress amplification for tumor‐specific disulfiram (DSF) chemotherapy and intensified chemodynamic therapy by synergistic in situ “nontoxicity–toxicity” activation is developed. Notably, CeO2 can not only act as a morphological “regulator,” but also serve as a cascaded enzyme‐mimetic catalyst via tumor‐microenvironment‐responsive cascaded‐logical programmable valence conversion. Once internalized inside tumor cells, the nanozyme can be degraded by lysosomal acidity to release nontoxic DSF and Cu2+, which can trigger in situ “Cu2+‐DSF” chelation, generating a highly toxic Cu(DTC)2 for in situ chemotherapy. Moreover, the enriched CeO2 with catalase‐mimetic activity can decompose the endogenous H2O2 into O2, which can relieve the hypoxia to enhance the chemotherapeutic efficacy. Furthermore, the simultaneously generated Ce3+ can exert peroxidase‐mimetic activity to catalyze H2O2 into hydroxyl radicals (•OH) for chemodynamic therapy. This Fenton‐like chemistry is accompanied by the regeneration of Ce4+, which can deplete the intracellular overproduced GSH to amplify the oxidative stress. Therefore, this nanozyme can provide an alternative to precise cancer treatment.